A unicenter, randomized, double-blind, parallel-group, placebo-controlled study of Melatonin as an Adjunct in patients with acute myocaRdial Infarction undergoing primary Angioplasty. The Melatonin Adjunct in the acute myocaRdial Infarction treated with Angioplasty (MARIA) trial: Study design and rationale

Contemporary Clinical Trials

Volumn 28, Issue 4, 2007, Pages 532-539

  Dominguez Rodriguez, Alberto ^a   Abreu Gonzalez, Pedro ^b   Garcia Gonzalez, Martín J ^a   Kaski, Juan Carlos ^c   Reiter, Russel J ^d   Jimenez Sosa, Alejandro ^a  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^b UNIVERSIDAD DE LA LAGUNA   (Spain)

^c ST GEORGE S HOSPITAL   (United Kingdom)

^d Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Acute myocardial infarction; Melatonin; Phase 2; Primary angioplasty; Study design

Indexed keywords

2 HYDROXYBUTYRATE DEHYDROGENASE; MELATONIN; PLACEBO;

ACUTE HEART INFARCTION; ADJUVANT THERAPY; ADULT; AGED; ANGIOPLASTY; AREA UNDER THE CURVE; ARTICLE; BLEEDING; CARDIOGENIC SHOCK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HEART ARREST; HEART FAILURE; HEART INFARCTION SIZE; HEART VENTRICLE ARRHYTHMIA; HOSPITAL READMISSION; HUMAN; ISCHEMIA; MAJOR CLINICAL STUDY; PARALLEL DESIGN; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RESUSCITATION; REVASCULARIZATION; STROKE;

ADULT; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIOXIDANTS; AREA UNDER CURVE; CAUSE OF DEATH; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROXYBUTYRATE DEHYDROGENASE; INFUSIONS, INTRAVENOUS; MALE; MELATONIN; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; PATIENT READMISSION; PROSPECTIVE STUDIES; RECURRENCE; RESEARCH DESIGN;

EID: 34248564577     PISSN: 15517144     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cct.2006.10.007     Document Type: Article

References (51)

1. Antman E.M., Ande D.T., Armstrong P.W., et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction - executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (writing committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). Circulation 110 (2004) 588-636
2. Thompson P.L., Fletcher E., and Kaavatis V. Enzymatic indices of myocardial necrosis; influence on short-and long-term prognosis after myocardial infarction. Circulation 59 (1979) 113-119
3. Braunwald E. Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction and improved survival. Should the paradigm be expanded?. Circulation 79 (1989) 441-444
4. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1,000 patients. Lancet 343 (1994) 311-322
5. GUSTO IIb Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 336 (1997) 1621-1628
6. Kloner R.A. Does reperfusion injury exist in humans?. J Am Coll Cardiol 21 (1993) 537-545
7. Ambrosio G., and Tritto I. Reperfusion injury: experimental evidence and clinical implications. Am Heart J 138 (1999) 69-75
8. Moens A.L., Claeys M.J., Timmermans J.P., and Vrints C.J. Myocardial ischemia/reperfusion-injury, a clinical view on a complex pathophysiological process. Int J Cardiol 100 (2005) 179-190
9. Abe J.L., and Berk B.C. Reactive oxygen species as mediators of signal transduction in cardiovascular disease. Trends Cardiovasc Med 8 (1998) 59-64
10. Reiter R.J. Pineal melatonin. Cell biology of its synthesis and of its physiological interactions. Endocr Rev 12 (1991) 151-180
11. Reiter R.J., and Tan D.X. Melatonin: a novel protective agent against oxidative injury of the ischemic / reperfused heart. Cardiovasc Res 58 (2003) 10-19
12. Hardeland R., Reiter R.J., Poeggeler B., and Tan D.X. The significance of the metabolism of the neurohormone melatonin: antioxidative protection and formation of bioactive substances. Neurosci Biobehav Rev 17 (1993) 347-357
13. Reiter R.J., Melchiorri D., Sewerynek E., et al. A review of the evidence supporting melatonin's role as an antioxidant. J Pineal Res 18 (1995) 1-11
14. Tan D.X., Manchester L.C., Reiter R.J., et al. Melatonin directly scavenges hydrogen peroxide: a potentially new metabolic pathway of melatonin biotransformation. Free Radic Biol Med 29 (2000) 1177-1185
15. 2-formyl-5-methoxykynuramine, a biogenic amine and melatonin metabolite, function as a potent antioxidant. FASEB J 15 (2001) 2294-2296
16. Tan D.X., Manchester L.C., Reiter R.J., et al. Cyclic 3-hydroxy-melatonin: a melatonin metabolite generated as a result of hydroxy radical scavenging. Biol Signals Recept 8 (1999) 70-74
17. Pieri C., Marra M., Moroni F., Recchioni R., and Marcheselli F. Melatonin: a peroxyl radical scavenger more effective than vitamin E. Life Sci 55 (1994) PL271-PL276
18. Rodriguez C., Mayo J.C., Sainz R.M., et al. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res 36 (2004) 1-9
19. Leon J., Acuna-Castroviejo D., Escames G., Tan D.X., and Reiter R.J. Melatonin mitigates mitochondrial malfunction. J Pineal Res 38 (2005) 1-9
20. Lagneaux C., Joyeux M., Demenge P., Ribuot C., and Godin-Ribuot D. Protective effects of melatonin against ischemia-reperfusion injury in the isolated rat heart. Life Sci 66 (2000) 503-509
21. Chen Z., Chua C.C., Gao J., Hamdy R.C., and Chua B.H.L. Protective effect of melatonin on myocardial infarction. Am J Physiol Heart Circ Physiol 284 (2002) H1618-H1624
22. Lee Y.M., Chen H.R., Hsiao G., Sheu J.R., and Yen M.H. Protective effects of melatonin on myocardial ischemia/reperfusion injury in vivo. J Pineal Res 33 (2002) 72-80
23. Sahna E., Acet A., Ozer M.K., and Olmez E. Myocardial ischemia-reperfusion in rats: reduction of infarct size by either supplemental physiologic or pharmacological doses of melatonin. J Pineal Res 33 (2002) 234-238
24. Gitto E., Karbownik M., Reiter R.J., et al. Effects of melatonin treatment in septic newborns. Pediatr Res 50 (2001) 756-760
25. Gitto E., Reiter R.J., Amodio A., et al. Early indicators of chronic lung disease in preterm infants with respiratory distress syndrome and their inhibition by melatonin. J Pineal Res 36 (2004) 250-255
26. Mallo C., Zaidan R., Galy C., et al. Pharmacokinetics of melatonin in man after intravenous infusión and bolus injection. Eur J Clin Pharmacol 38 (1990) 297-310
27. Schröder R., Dissmann R., Bruggemann T., et al. Extent of early ST segment elevation resolution: a simple but strong predictor of outcome in patients with acute myocardial infarction. J Am Coll Cardiol 24 (1994) 384-391
28. Fleiss J.L. Statistical Methods for Rates and Proportions (1981), Wiley, New York 217-234
29. Dissmann R., Linderer T., and Schröder R. Estimation of enzymatic infarct size: direct comparison of the marker enzymes creatine kinase and α-hydroxybutyrate dehydrogenase. Am Heart J 135 (1998) 1-9
30. Zeymer U., Suryapranata H., Monassier J.P., et al. Evaluation of the safety and cardioprotective effects of Eniporide, a specific sodium/hydrogen exchange inhibitor, given as adjunctive therapy to reperfusion in patients with acute myocardial infarction. Heart Drug 1 (2001) 71-76
31. Van der Laarse A., Hermens W.T., Hollaar L., et al. Assessment of myocardial damage in patients with acute myocardial infarction by serial measurements for serum alpha-hydroxybutyrate dehydrogenase levels. Am Heart J 107 (1984) 248-260
32. Schiller N., Shah P., Crawford M., et al. American Society of echocardiography committee on standards, subcommittee on quantification of two-dimensional echocardiograms. J Am Soc Echocardiogr 2 (1989) 358-367
33. Van de Werf F., Ardissino D., Betriu A., et al. Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 24 (2003) 28-66
34. Hermens W.T., van der Veen F.H., Willems G.M., and Reneman R.S. Enzymatic infarct size and its significance for evaluation of thrombolytic therapy after acute myocardial infarction. Circulation 81 (1990) 1719-1720
35. Zeymer U., Suryapranata H., Monassier J.P., et al. The Na(+)/H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial. J Am Coll Cardiol 38 (2001) 1644-1650
36. Mahaffey K.W., Puma J.A., Barbagelata A., et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction. J Am Coll Cardiol 34 (1999) 1711-1720
37. SAS Institute Inc. SAS/STAT user's guide, version 8 (1999), SAS Institute Inc, Cary (NC)
38. O'Brien P.C., and Fleming T.R. A multiple testing procedure for clinical trials. Biometrics 35 (1979) 549-556
39. Reiter R.J. The aging pineal gland and its physiological consequences. BioEssays 14 (1992) 169-175
40. Brugger P., Marktl W., and Herold M. Impaired nocturnal secretion of melatonin in coronary artery disease. Lancet 345 (1995) 1408
41. Brugger P., and Herold M. Human melatonin and cortisol circadian rhythms in patients with coronary heart disease. Biol Rhythm Res 29 (1998) 121-128
42. Sakotnik A., Liebmann P.M., Stoschitsky K., et al. Decreased melatonin synthesis in patients with coronary artery disease. Eur Heart J 20 (1999) 1314-1317
43. Altun A., Yaprak M., Aktoz M., Vardar A., Betul U.A., and Ozbay G. Impaired nocturnal synthesis of melatonin in patients with cardiac syndrome X. Neurosci Lett 327 (2002) 143-145
44. Dominguez-Rodriguez A., Abreu-Gonzalez P., Garcia M., Sanchez J., Marrero M., and de Armas-Trujillo D. Decreased nocturnal melatonin levels during acute myocardial infarction. J Pineal Res 33 (2002) 248-252
45. Dominguez-Rodriguez A., Abreu-Gonzalez P., Garcia M., et al. Light/dark patterns of interleukin-6 in relation to the pineal hormone melatonin in patients with acute myocardial infarction. Cytokine 26 (2004) 89-93
46. Domínguez-Rodríguez A., Abreu-Gonzalez P., Ferrer J., and Vargas M. Oxidative stress and melatonin in the acute myocardial infarction. Heart 90 Suppl III (2004) A1
47. Dominguez-Rodriguez A., Abreu-Gonzalez P., Garcia-Gonzalez M., Ferrer-Hita J., Vargas M., and Reiter R.J. Elevated levels of low-density lipoprotein and impaired nocturnal synthesis of melatonin in patients with myocardial infarction. Atherosclerosis 180 (2005) 101-105
48. Dominguez-Rodriguez A., Abreu-Gonzalez P., Garcia-Gonzalez M., Ferrer J., and Kaski J.C. Relation of nocturnal melatonin levels to C-reactive protein concentration in patients with ST-segment elevation myocardial infarction. Am J Cardiol 97 (2006) 10-12
49. Dominguez-Rodriguez A., Abreu-Gonzalez P., Garcia-Gonzalez M., and Reiter RJ. Prognostic value of nocturnal melatonin levels as a novel marker in patients with ST-segment elevation myocardial infarction. Am J Cardiol 97 (2006) 1162-1164
50. Dominguez-Rodriguez A., Abreu-Gonzalez P., Garcia-Gonzalez M.J., Kaski J.C., and Reiter R.J. The melatonin adjunct in the acute myocardial infarction treated with primary angioplasty: study design and rationales (MARIA TRIAL) [abstract]. Atherosclerosis 7 Supl 3 (2006) 122
51. Benot S., Goberna R., Reiter R.J., Garcia-Maurino S., Osuna C., and Guerrero J.M. Physiological levels of melatonin contribute to the antioxidant capacity of human serum. J Pineal Res 27 (1999) 59-64